BerGenBio ASA (BGBIOO.XC)
| Previous close | 0.2683 |
| Open | 0.2905 |
| Bid | 0.2350 x N/A |
| Ask | 0.7840 x N/A |
| Day's range | 0.2683 - 0.2683 |
| 52-week range | 0.1000 - 26.8300 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 10.487M |
| Beta (5Y monthly) | 1.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -55.4100 |
| Earnings date | 21 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireBerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development
BerGenBio ASA (OSE: BGBIO), a clinical-stage bio-pharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and provided a business update.
PR NewswireBerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that it has entered into a clinical trial agreement with the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and Swedish Orphan Biovitrum AB (Sobi®) (STO:SOBI), a specialized international biopharmaceutical company.
PR NewswireBerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation
BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today it has initiated the Phase 2a portion of the BGBC016 clinical study of its selective AXL inhibitor bemcentinib in combination with standard of care therapy in first-line Non Small Cell Lung Cancer (NSCLC) patients harboring a STK11 mutation (STK11m).
